Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The risk of second primary malignancies in colorectal cancer patients using calcium channel blockers

J. Halámková, L. Bohovicová, L. Pehalová, T. Kazda, R. Goněc, T. Staněk, L. Mouková, D. Adámková Krákorová, Š. Kozáková, M. Svoboda, R. Demlová, L. Gabrielová, L. Hernychová, I. Kiss

. 2023 ; 13 (1) : 3490. [pub] 20230301

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003908

Calcium channel blockers are among the most commonly used agents in the treatment of cardiovascular diseases. There are several known side-effects associated with their long-term use, whereas other potential adverse effects are yet to be proven. This study aims to evaluate the association between calcium channel blockers exposure and the incidence of second primary malignancy. We established a cohort of 1401 patients with colorectal cancer diagnosed in our institution between January 2003 and December 2016. Patients were followed-up until December 2020. The tumor characteristics and basic clinical data including medication information were obtained from the hospital information system database. Second malignancy was detected in 301 patients (21.5%), and occurred in 27.8% of patients who used calcium channel blockers compared to only 19.9% among non-users. Their use was associated with an increased incidence of bladder cancer in particular. Subanalysis of patients with second malignancy displayed a higher proportion of right-sided colon cancer compared to rectal carcinoma in non-users. Survival analysis revealed significantly better outcomes in early-stage colorectal cancer patients without a history of calcium channel blockers treatment or second primary malignancy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003908
003      
CZ-PrNML
005      
20230425140937.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-023-29535-7 $2 doi
035    __
$a (PubMed)36859505
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Halámková, Jana $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    14
$a The risk of second primary malignancies in colorectal cancer patients using calcium channel blockers / $c J. Halámková, L. Bohovicová, L. Pehalová, T. Kazda, R. Goněc, T. Staněk, L. Mouková, D. Adámková Krákorová, Š. Kozáková, M. Svoboda, R. Demlová, L. Gabrielová, L. Hernychová, I. Kiss
520    9_
$a Calcium channel blockers are among the most commonly used agents in the treatment of cardiovascular diseases. There are several known side-effects associated with their long-term use, whereas other potential adverse effects are yet to be proven. This study aims to evaluate the association between calcium channel blockers exposure and the incidence of second primary malignancy. We established a cohort of 1401 patients with colorectal cancer diagnosed in our institution between January 2003 and December 2016. Patients were followed-up until December 2020. The tumor characteristics and basic clinical data including medication information were obtained from the hospital information system database. Second malignancy was detected in 301 patients (21.5%), and occurred in 27.8% of patients who used calcium channel blockers compared to only 19.9% among non-users. Their use was associated with an increased incidence of bladder cancer in particular. Subanalysis of patients with second malignancy displayed a higher proportion of right-sided colon cancer compared to rectal carcinoma in non-users. Survival analysis revealed significantly better outcomes in early-stage colorectal cancer patients without a history of calcium channel blockers treatment or second primary malignancy.
650    _2
$a lidé $7 D006801
650    12
$a sekundární malignity $7 D016609
650    _2
$a blokátory kalciových kanálů $7 D002121
650    12
$a kardiovaskulární nemoci $7 D002318
650    _2
$a kolon $7 D003106
650    12
$a nežádoucí účinky léčiv $7 D064420
650    12
$a nádory rekta $7 D012004
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bohovicová, Lucia $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Pehalová, Lucie $u Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kazda, Tomáš $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Goněc, Roman $u Department of Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Staněk, Teodor $u Department of General Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Mouková, Lucie $u Department of Gynecologic Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Adámková Krákorová, Dagmar $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Kozáková, Šárka $u Department of Pharmacy, University Hospital Brno, Brno, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Demlová, Regina $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Clinical Trial Unit, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Gabrielová, Lucie $u Department of Surgical Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Breast, Skin and Oncoplastic Surgery, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Hernychová, Lenka $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. kiss@mou.cz $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic. kiss@mou.cz $u Masaryk Memorial Cancer Institute, Žlutý Kopec 7, 656 53, Brno, Czech Republic. kiss@mou.cz
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 3490
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36859505 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140934 $b ABA008
999    __
$a ok $b bmc $g 1924517 $s 1190117
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 1 $d 3490 $e 20230301 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace